Table 1.
Subject demographics
| Study | Age (months) | Patient weight (kg) | Gender | Lung volume* (L) | Study indication |
|---|---|---|---|---|---|
| 1 | 0.1 (3 d) | NA | F | 0.13 | Evaluate for metastatic disease |
| 2 | 0.5 (16 d) | NA | F | 0.10 | Pre-bone marrow transplant |
| 3 | 2 | 3.1 | M | 0.17 | Complete tracheal rings |
| 4 | 3 | NA | F | 0.17 | Evaluate for metastatic disease |
| 5 | 4 | 6.3 | F | 0.19 | Evaluate for metastatic disease |
| 6 | 4 | 5.6 | F | 0.18 | Evaluate for metastatic disease |
| 7 | 8 | NA | M | 0.25 | Evaluate for metastatic disease |
| 8 | 9 | 6.9 | M | 0.21 | Evaluate for metastatic disease |
| 9 | 12 | 7.5 | F | 0.41 | Laryngomalacia |
| 10 | 16 | 9.6 | M | 0.61 | Evaluate for metastatic disease |
| 11 | 21 | 12.0 | M | 0.59 | Evaluate for metastatic disease |
| 12 | 24 | 14.4 | M | 0.46 | Prior pulmonary infection |
| 13 | 24 | 11.6 | M | 0.77 | Laryngomalacia |
| 14 | 24 | 12.0 | F | 0.26 | Evaluate for metastatic disease |
| 15 | 25 | 11.9 | F | 0.73 | Resolved URI |
| 16 | 31 | NA | F | 0.38 | Evaluate for metastatic disease |
| 17 | 33 | 12.2 | F | 0.42 | Evaluate for metastatic disease |
| 18 | 34 | NA | F | 0.64 | Resolved pneumonia |
| 19 | 41 | 12.2 | F | 0.63 | Evaluate for metastatic disease |
| 20 | 46 | 17.0 | M | 0.91 | Evaluate for metastatic disease |
| 21 | 49 | 17.7 | F | 0.85 | Evaluate for metastatic disease |
| 22 | 49 | 20.4 | M | 0.75 | Chest radiograph abnormality |
| 23 | 49 | 18.0 | M | 1.01 | Glottic papillomatosis |
| 24 | 50 | 21.0 | M | 0.72 | Evaluate for metastatic disease |
| 25 | 51 | 13.0 | F | 0.53 | Evaluate for metastatic disease |
| 26 | 52 | 20.3 | F | 0.68 | Evaluate for metastatic disease |
| 27 | 58 | 20.8 | M | 1.12 | Resolved URI |
| 28 | 58 | 20.0 | F | 0.95 | Evaluate for metastatic disease |
| 29 | 64 | 16.8 | F | 0.94 | Evaluate for metastatic disease |
| 30 | 66 | 18.4 | M | 0.58 | Resolved URI |
| 31 | 66 | NA | F | 0.86 | Fever |
| 32 | 67 | 17.6 | M | 1.21 | Resolved URI |
| 33 | 67 | 23.1 | F | 0.65 | Evaluate for metastatic disease |
| 34 | 68 | 27.1 | M | 0.79 | Evaluate for metastatic disease |
| 35 | 69 | NA | F | 1.72 | Resolved pneumonia |
| 36 | 70 | 22.8 | F | 1.09 | Evaluate for metastatic disease |
| 37 | 71 | 24.9 | M | 0.85 | Evaluate for metastatic disease |
| 38 | 77 | 20.0 | F | 0.70 | Evaluate for metastatic disease |
| 39 | 78 | 22.6 | M | 1.60 | Evaluate for metastatic disease |
| 40 | 79 | 21.6 | M | 1.63 | Evaluate for metastatic disease |
| 41 | 82 | 21.6 | F | 1.22 | Evaluate for metastatic disease |
| 42 | 83 | 21.6 | M | 1.07 | Evaluate for metastatic disease |
*
Lung volume includes atelectasis as measured from CT images
d days, f female, m male, NA not available, URI upper respiratory infection